When a patient presents with a first acute event of immune-mediated thrombotic thrombocytopenic purpura (iTTP), the treatment approach is specific to this initial presentation. Evidence-based recommendations define a multi-component regimen for this scenario.
The patient has immune-mediated thrombotic thrombocytopenic purpura (iTTP) and is experiencing their first acute event. Guideline recommendations specifically address this presentation, supporting a combination treatment strategy at this initial episode.
Therapeutic plasma exchange (TPE) is a central component of management, used in combination with immunosuppressive agents — the full protocol details which additional therapies are recommended alongside TPE for this first acute event…
DOI: 10.1111/jth.15010
For patients with iTTP experiencing a first acute event, the panel recommends the addition of corticosteroids to therapeutic plasma exchange (TPE) over TPE alone.
For patients with iTTP experiencing their first acute event, the panel suggests the addition of rituximab to corticosteroids and TPE over corticosteroids and TPE alone.
View source ↗